Table 1 Baseline characteristics
Characteristic | DOAC group (n = 167) | Parenteral anticoagulant group (n = 135) | P value |
|---|---|---|---|
Age, years, Median (Q1-Q3) | 70.5 (60–79) | 71 (63–81) | 0.4 |
Body Mass Index, kg/m², Median (Q1-Q3) | 28.75 (24.2–35) | 30 (26.4–36.5) | 0.97 |
Gender, male, n (%) | 83 (50) | 52 (39) | 0.07 |
Admission Unit, n (%) | 0.39 | ||
Medical ICU | 101 (60) | 89 (66) | |
Coronary Care Unit | 66 (40) | 46 (34) | |
Admission Diagnoses, n (%) | 0.01 | ||
Respiratory failure | 45 (27) | 34 (25) | |
Sepsis and infections | 20 (12) | 37 (27) | |
Cardiovascular conditions | 70 (42) | 50 (37) | |
Renal and metabolic conditions | 12 (7) | 7 (5) | |
Hepatic conditions | 3 (2) | 1 (1) | |
Other | 17 (10) | 6 (4) | |
Comorbidities, n (%) | |||
Cancer | 14 (8) | 11 (8) | 1 |
Diabetes mellitus | 117 (70) | 83 (61) | 0.15 |
Congestive heart failure | 99 (59) | 63 (47) | 0.04 |
Chronic pulmonary disease | 36 (22) | 37 (27) | 0.3 |
Moderate to severe chronic kidney disease | 40 (24) | 41 (30) | 0.26 |
Cerebrovascular accident | 24 (14) | 10 (7) | 0.09 |
Peptic ulcer disease | 2 (1) | 0 (0) | 0.57 |
Anaemia | 1 (1) | 0 (0) | 1 |
Peripheral vascular disease | 7 (4) | 5 (4) | 1 |
Liver disease | 4 (2) | 2 (1) | 0.88 |
Hypercoagulable disorders | 5 (3) | 8 (6) | 0.34 |
APACHE III Score, Median (Q1-Q3) | 41 (29.2–52) | 44 (34–58) | 0.34 |
Laboratory at admission, Median (Q1-Q3) | |||
Haemoglobin, g/L | 119 (103–138) | 112 (99–134) | 0.11 |
Haematocrit, % | 37 (32–43) | 35 (31–43) | 0.14 |
Platelets, ×10⁹/L | 222 (182–280) | 258 (177–320) | 0.63 |
Creatinine clearance, mL/min | 59 (31–78) | 58 (33–89) | 0.87 |
Blood urea nitrogen, mmol/L | 8.4 (5.7–16.2) | 8.3 (5.6–14.9) | 0.83 |
INR | 1.1 (1-1.3) | 1.1 (1-1.3) | 0.91 |
Prothrombin time, seconds | 12.2 (11.6–13.6) | 12.1 (11.4–14.2) | 0.76 |
aPTT, seconds | 29 (26–34) | 28 (25–33) | 0.01 |
Outpatient DOAC Agent, n (%) | |||
Apixaban | 156 (93) | 130 (96) | 0.29 |
Rivaroxaban | 14 (8) | 4 (3) | 0.06 |
Edoxaban | 0 (0) | 0 (0) | NA |
Dabigatran | 2 (1) | 1 (1) | 1 |
Primary DOAC indication, n (%) | |||
Nonvalvular Atrial fibrillation | 130 (78) | 113 (84) | 0.18 |
History of deep vein thrombosis | 12 (7) | 6 (4) | 0.32 |
History of pulmonary embolism | 18 (11) | 6 (4) | 0.06 |
Acute myocardial infarction* | 6 (4) | 8 (6) | 0.39 |
Other thrombosis | 1 (1) | 2 (1) | 0.58 |